ES2539603T3 - Agente inductor de inmunidad - Google Patents
Agente inductor de inmunidad Download PDFInfo
- Publication number
- ES2539603T3 ES2539603T3 ES09805008.1T ES09805008T ES2539603T3 ES 2539603 T3 ES2539603 T3 ES 2539603T3 ES 09805008 T ES09805008 T ES 09805008T ES 2539603 T3 ES2539603 T3 ES 2539603T3
- Authority
- ES
- Spain
- Prior art keywords
- polypeptide
- agent
- immunity inducing
- cancer
- inducing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000036039 immunity Effects 0.000 title abstract description 15
- 230000001939 inductive effect Effects 0.000 title abstract description 14
- 239000003795 chemical substances by application Substances 0.000 abstract description 26
- 229920001184 polypeptide Polymers 0.000 abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 8
- 230000002265 prevention Effects 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 3
- 230000002434 immunopotentiative effect Effects 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000004528 gastrointestinal lymphoma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- -1 inhalers Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008202065 | 2008-08-05 | ||
| JP2008202065 | 2008-08-05 | ||
| PCT/JP2009/063881 WO2010016525A1 (ja) | 2008-08-05 | 2009-08-05 | 免疫誘導剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2539603T3 true ES2539603T3 (es) | 2015-07-02 |
Family
ID=41663742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09805008.1T Active ES2539603T3 (es) | 2008-08-05 | 2009-08-05 | Agente inductor de inmunidad |
| ES14185710.2T Active ES2619322T3 (es) | 2008-08-05 | 2009-08-05 | Agente inductor de inmunidad |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14185710.2T Active ES2619322T3 (es) | 2008-08-05 | 2009-08-05 | Agente inductor de inmunidad |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8454968B2 (Direct) |
| EP (2) | EP2837383B1 (Direct) |
| JP (2) | JP5691171B2 (Direct) |
| KR (3) | KR101669827B1 (Direct) |
| CN (2) | CN103751771B (Direct) |
| AU (2) | AU2009278385B2 (Direct) |
| BR (2) | BR122020027042B1 (Direct) |
| CA (1) | CA2732283C (Direct) |
| DK (2) | DK2324842T3 (Direct) |
| ES (2) | ES2539603T3 (Direct) |
| HU (1) | HUE031343T2 (Direct) |
| MX (2) | MX348464B (Direct) |
| PL (2) | PL2324842T3 (Direct) |
| PT (2) | PT2837383T (Direct) |
| RU (2) | RU2511039C2 (Direct) |
| WO (1) | WO2010016525A1 (Direct) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2471379T3 (es) | 2008-08-05 | 2014-06-26 | Toray Industries, Inc. | Método para detectar el cáncer |
| BRPI0911926A2 (pt) | 2008-08-05 | 2020-08-18 | Toray Industries, Inc | composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo. |
| DK2532365T3 (en) | 2010-02-04 | 2016-08-15 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER |
| ES2540858T3 (es) | 2010-02-04 | 2015-07-14 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención de cáncer |
| RU2624029C2 (ru) * | 2010-02-04 | 2017-06-30 | Торэй Индастриз, Инк. | Лекарственный препарат для лечения и/или профилактики рака |
| EP2532366B1 (en) | 2010-02-04 | 2016-09-07 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| ES2583777T3 (es) * | 2010-02-04 | 2016-09-22 | Toray Industries, Inc. | Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer |
| US8709418B2 (en) | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
| CN103547284B (zh) * | 2011-05-19 | 2015-11-25 | 东丽株式会社 | 免疫诱导剂 |
| PT2741085T (pt) | 2011-08-04 | 2017-06-30 | Toray Industries | Método para a deteção de cancro prancreático |
| US9180188B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| HUE030137T2 (en) * | 2011-08-04 | 2017-04-28 | Toray Industries | Pharmaceutical preparation for the treatment and / or prevention of cancer |
| PL2740793T3 (pl) * | 2011-08-04 | 2018-04-30 | Toray Industries, Inc. | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi |
| DK2740489T3 (en) | 2011-08-04 | 2017-01-16 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
| PT2740796T (pt) * | 2011-08-04 | 2017-07-26 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| US9175074B2 (en) | 2011-08-04 | 2015-11-03 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| KR102009236B1 (ko) | 2012-02-21 | 2019-08-09 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| RU2631804C2 (ru) | 2012-02-21 | 2017-09-26 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения или профилактики рака |
| JP6187255B2 (ja) | 2012-02-21 | 2017-08-30 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| KR102005308B1 (ko) | 2012-02-21 | 2019-07-30 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| AU2013241043B2 (en) * | 2012-03-30 | 2017-11-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gall bladder cancer |
| US9416193B2 (en) | 2012-03-30 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| CN104471403B (zh) | 2012-07-19 | 2017-03-01 | 东丽株式会社 | 癌的检测方法 |
| MX358772B (es) | 2012-07-19 | 2018-09-04 | Toray Industries | Metodo para detectar cancer. |
| KR102255616B1 (ko) | 2013-08-09 | 2021-05-25 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| ES2832523T3 (es) * | 2015-04-30 | 2021-06-10 | Toray Industries | Agente inductor de inmunidad |
| CA3041979A1 (en) * | 2016-10-28 | 2018-05-03 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| KR20200136935A (ko) * | 2018-03-30 | 2020-12-08 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CN109206502B (zh) * | 2018-09-26 | 2022-03-04 | 东北农业大学 | 一种猫干扰素ω及其制备方法和在抗病毒中的应用 |
| CN109206501B (zh) * | 2018-09-26 | 2022-03-04 | 东北农业大学 | 猫干扰素ω、其编码基因及其在抗病毒方面的应用 |
| MX2023000163A (es) * | 2020-06-26 | 2023-07-03 | Phaim Pharma Ltd | Plataforma terapéutica de modulador antigénico del sistema inmune (aim) para la psoriasis y otras enfermedades autoinmunes. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| PL200772B1 (pl) * | 1998-07-14 | 2009-02-27 | Corixa Corp | Izolowany polipeptyd, fuzja białkowa oraz ich zastosowanie, izolowany epitop komórki T, wektor ekspresyjny, komórka gospodarza, sposób stymulowania i/lub namnażania komórek T, izolowana populacja komórek T, kompozycja i jej zastosowanie oraz izolowane komórki T |
| WO2002083070A2 (en) * | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| US20030190640A1 (en) * | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| MXPA04003901A (es) * | 2001-11-07 | 2004-07-08 | Cytos Biotechnology Ag | Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas. |
| US20050003390A1 (en) * | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20060121029A1 (en) * | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| EP1991701A4 (en) | 2006-02-14 | 2010-03-17 | Dana Farber Cancer Inst Inc | COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER |
| US20080107668A1 (en) * | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| KR20080075722A (ko) | 2007-02-13 | 2008-08-19 | 엘지이노텍 주식회사 | 튜너 |
| JP4826496B2 (ja) | 2007-02-16 | 2011-11-30 | 三菱マテリアル株式会社 | 電解メッキ用アノード電極取付構造 |
| WO2013143026A1 (en) * | 2012-03-31 | 2013-10-03 | Abmart (Shanghai) Co., Ltd | Peptide and antibody libraries and uses thereof |
| US20140357512A1 (en) * | 2013-06-03 | 2014-12-04 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase (hdac) biomarkers in multiple myeloma |
-
2009
- 2009-08-05 PT PT141857102T patent/PT2837383T/pt unknown
- 2009-08-05 EP EP14185710.2A patent/EP2837383B1/en active Active
- 2009-08-05 MX MX2015000895A patent/MX348464B/es unknown
- 2009-08-05 KR KR1020117001808A patent/KR101669827B1/ko active Active
- 2009-08-05 ES ES09805008.1T patent/ES2539603T3/es active Active
- 2009-08-05 MX MX2011001113A patent/MX339277B/es active IP Right Grant
- 2009-08-05 BR BR122020027042-0A patent/BR122020027042B1/pt active IP Right Grant
- 2009-08-05 ES ES14185710.2T patent/ES2619322T3/es active Active
- 2009-08-05 KR KR1020177032975A patent/KR102009241B1/ko active Active
- 2009-08-05 KR KR1020167029224A patent/KR20160127146A/ko not_active Ceased
- 2009-08-05 CN CN201410047289.2A patent/CN103751771B/zh active Active
- 2009-08-05 CA CA2732283A patent/CA2732283C/en active Active
- 2009-08-05 HU HUE14185710A patent/HUE031343T2/hu unknown
- 2009-08-05 PL PL09805008T patent/PL2324842T3/pl unknown
- 2009-08-05 CN CN200980130313.6A patent/CN102112146B/zh active Active
- 2009-08-05 WO PCT/JP2009/063881 patent/WO2010016525A1/ja not_active Ceased
- 2009-08-05 PT PT98050081T patent/PT2324842E/pt unknown
- 2009-08-05 US US13/056,122 patent/US8454968B2/en active Active
- 2009-08-05 RU RU2011108315/10A patent/RU2511039C2/ru active
- 2009-08-05 DK DK09805008.1T patent/DK2324842T3/da active
- 2009-08-05 DK DK14185710.2T patent/DK2837383T3/en active
- 2009-08-05 JP JP2009546597A patent/JP5691171B2/ja active Active
- 2009-08-05 AU AU2009278385A patent/AU2009278385B2/en active Active
- 2009-08-05 PL PL14185710T patent/PL2837383T3/pl unknown
- 2009-08-05 EP EP09805008.1A patent/EP2324842B1/en active Active
- 2009-08-05 BR BRPI0912462-4A patent/BRPI0912462B1/pt active IP Right Grant
-
2013
- 2013-05-06 US US13/888,137 patent/US9592281B2/en active Active
- 2013-12-19 RU RU2013156620A patent/RU2639518C2/ru active
-
2014
- 2014-11-05 JP JP2014225626A patent/JP5962739B2/ja active Active
-
2015
- 2015-08-07 AU AU2015210461A patent/AU2015210461B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2539603T3 (es) | Agente inductor de inmunidad | |
| JP7175334B2 (ja) | 免疫刺激剤による癌治療 | |
| Niscola et al. | Mucositis in patients with hematologic malignancies: an overview | |
| ES2392873T3 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial humano de tipo 2 | |
| CN105338977B (zh) | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 | |
| ES2661216T3 (es) | Método combinado para tratar el cáncer o un estado precanceroso | |
| US20120251441A1 (en) | Adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of clinical manifestations associated with diseases like cachexia and correction of adverse effects of drugs such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier specially selected and other substances with antineoplastic action and/or other treatments | |
| Moslemi et al. | Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: a double blind, randomized controlled clinical trial | |
| ES2664568T3 (es) | La aplicación parenteral de aceite de pescado/DHA + EPA antes de, o bien con el comienzo de la quimioterapia | |
| Zhang et al. | Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice | |
| BR112015007549B1 (pt) | Produto de argila e seus usos | |
| AU2019236645A1 (en) | Cancer therapy | |
| CN1649645A (zh) | 用于治疗肾癌的缩酚肽 | |
| CN104039952A (zh) | 用于树突状细胞癌症疫苗的小分子增强剂 | |
| JP2022528915A (ja) | 腫瘍を治療することの方法 | |
| Lawrence et al. | Symptomatic management of primary acute gastroenteritis | |
| Hussain et al. | Lactoferrin in Aquaculture: A Holistic Review of its Health Benefits and Functional Feed Application. | |
| CN102482334A (zh) | Sparc血管发生结构域及使用方法 | |
| ES2208330T3 (es) | Composiciones para modular la respuesta nmune y para el tratamiento de la enfermedad inflamatoria. | |
| JP2018177667A (ja) | 炎症性腸疾患の予防又は治療用組成物 | |
| BR112021011222A2 (pt) | Inibidores de cxcr7 para o tratamento de câncer | |
| ES2842431T3 (es) | Composición para prevenir o tratar mucositis que comprende NecroX como ingrediente eficaz | |
| CN104622874B (zh) | Ccr4拮抗剂在抑制癌生长及转移中的应用 | |
| CN102755342B (zh) | 复方对乙酰氨基酚注射液及其制备方法 | |
| Baden et al. | Successful Neoadjuvant Chemotherapy and Surgical Removal of a Nonmetastatic Testicular Round Cell Tumor in a Solomon Island Eclectus Parrot (Eclectus roratus solomonensis) |